Ligand Pharmaceuticals Inc

Latest Ligand Pharmaceuticals Inc News and Updates

  • uploads///Graph
    Company & Industry Overviews

    Analysts’ Recommendations for United Therapeutics

    In 2Q17, United Therapeutics (UTHR) reported revenue of ~$445 million, representing year-over-year growth of around 8%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Ligand Pharmaceuticals Focuses on Increasing Returns for Shareholders

    Ligand Pharmaceuticals has developed a product portfolio that spans more than 700 patents offering varying degrees of protection to the assets.

    By Margaret Patrick
  • uploads///portfolio
    Company & Industry Overviews

    Ligand Pharmaceuticals’s Portfolio Pyramid as Its Valuation Catalyst

    Ligand Pharmaceuticals’s (LGND) product portfolio has expanded from nine programs in 2008 to 140+ programs in 2016.

    By Jillian Dabney
  • uploads///pill _
    Healthcare

    Why Ligand Pharmaceuticals Tanked 25%

    Today, US pharmaceutical firm Ligand Pharmaceuticals (LGND) fell 25% from yesterday’s closing price to a low of $98.86 for the day.

    By Jitendra Parashar
  • uploads///Graph
    Company & Industry Overviews

    Promacta and Jakavi May Boost Novartis’s Oncology Segment Revenues

    Jakavi reported sales of $228.0 million in 4Q17, which is a year-over-year rise of 33.0% on a constant currency basis.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Analysts Recommend for Alnylam Pharmaceuticals and Peers

    On September 20, 2017, Alnylam Pharmaceuticals (ALNY) announced positive top-line results from phase three trial APOLLO.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Analysts Recommend for Acadia Pharmaceuticals in September

    Of the nine analysts covering Acadia Pharmaceuticals in September 2017, two rated the stock a “strong buy,” six rated it a “buy,” and one rated it a “hold.”

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Captisol-Enabled Prexasertib May Be Major Growth Driver for Ligand

    Eli Lilly’s (LLY) Captisol-enabled drug Prexasertib is currently being evaluated in multiple oncology indications such as head and neck cancer, small-cell lung cancer (or SCLC), and advanced metastatic cancer.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Sparsentan May Be Solid Near-Term Growth Driver for Ligand

    With Sparsentan, Retrophin and Ligand Pharmaceuticals could become major nephrology players similar to peers such as Amgen (AMGN), AstraZeneca (AZN), and Bristol-Myers Squibb (BMY).

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Ligand Pharmaceuticals Projects Higher Average Royalty Rate for Promacta

    Ligand Pharmaceuticals (LGND) receives royalties from Novartis on Promacta’s sales according to a tiered annual payment structure.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Promacta: A Major Growth Driver for Ligand Pharmaceuticals in 2017

    Promacta was discovered by Ligand Pharmaceuticals (LGND) and GlaxoSmithKline (GSK) as a part of their thrombopoietin (or TPO) receptor agonist research collaboration.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Technology Platforms and Research Programs Drive LGND’s Partnerships

    Ligand Pharmaceuticals (LGND) has entered multiple fully funded partnerships by licensing its technology platforms such as OmniAb, Captisol, LTP Technology, and SUREtechnology Platform.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Fully Funded Partnerships May Drive Growth for Ligand Pharmaceuticals

    Ligand Pharmaceuticals (LGND) expects its licensees to invest ~$2.0 billion for advancing more than 155 partnered research and development programs in 2017.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Ligand Pharmaceuticals’ Shots-on-Goal Business Model

    Ligand Pharmaceuticals (LGND) has developed a business model called Shots-on-Goal, which is based on fully funded partnerships.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Analysts’ Recommendations for Ligand Pharmaceuticals and Peers in 2017

    In 2Q17, Ligand Pharmaceuticals (LGND) reported revenues of ~$28.0 million, representing year-over-year growth of ~43.4%. LGND received ~$14.2 million in royalties, a year-over-year rise of 45.7%.

    By Margaret Patrick
  • uploads///Chart  Keytruda Revenues
    Company & Industry Overviews

    How Did Keytruda Perform in 1Q17?

    Merck (MRK) launched Keytruda in 4Q14 and reported global sales of $584 million for 1Q17. As a result, the company reported ~134% growth in revenues compared to $249 million in 1Q16.

    By Mike Benson
  • uploads///annual revenue projections
    Company & Industry Overviews

    What Is Ligand Pharmaceuticals’s Expected Revenue Growth in 2016?

    Ligand Pharmaceuticals (LGND) is a high-growth company with a comparatively low-risk business model. It earns most of its revenue from royalty and license fees.

    By Jillian Dabney
  • uploads///Part  Graph
    Company & Industry Overviews

    Agios Stock Rises on Higher Trading Volumes on June 8

    Three analysts recommended a “buy” for Agios (AGIO), eight analysts recommended a “hold,” and no analysts recommended a “sell” for the stock. Agios has a weight of 2.2% in XBI’s portfolio.

    By Peter Neil
  • uploads///Chart
    Company & Industry Overviews

    Ionis Pharmaceuticals: Valuation Compared to Its Peers

    In this series, we’ll be looking at Ionis Pharmaceuticals’ (IONS) products and other factors that drive its revenues. This will give us a better understanding of what drives Ionis’s revenues.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Incyte Continues Its Growth Spree in 2015

    Incyte is a biopharmaceutical company that’s focused on the discovery, development, and commercialization of oncology drugs.

    By Mike Benson
  • © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.